← Leaderboards
Aaron N Hata
Massachusetts General Hospital
$5,868,906
Attributed
$8,229,816
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,229,816 · 5
By mechanism
R01$5,409,102 · 3
U01$1,924,314 · 1
K08$896,400 · 1
Top collaborators
- Jessica Jiyeong Lin3 shared
- Henning Willers3 shared
- Zofia Piotrowska2 shared
- Lecia V. Sequist2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Ben Z Stanger$14,778,829
- Alice T Shaw$3,731,101
- Jessica Jiyeong Lin$1,690,059
- Dai Fukumura$13,639,390
- Jeffrey A Engelman$5,049,484
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorGenomicsMalignant Neoplasm Of LungResistanceResistance MechanismMalignant NeoplasmsResponseTargeted TreatmentFutureNon-Small-Cell Lung CarcinomaMutationAcquired Drug ResistanceCellsEpidermal Growth Factor ReceptorNeoplastic CellMutantAutomobile DrivingSamplingOncogenicSignal PathwayImmuneClinically RelevantCancer PatientNon-Genomic
Grant awards (20)
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$417,500
R01 · FY2025 · CA · contact PI
Non-genomic resistance mechanisms in EGFR-mutant lung cancer$392,337
R01 · FY2025 · CA · contact PI
Mechanisms driving lung cancer evolution during targeted kinase inhibitor treatment$528,861
R01 · FY2024 · CA · contact PI
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$396,625
R01 · FY2024 · CA · contact PI
Non-genomic resistance mechanisms in EGFR-mutant lung cancer$372,721
R01 · FY2024 · CA · contact PI
Mechanisms driving lung cancer evolution during targeted kinase inhibitor treatment$483,862
R01 · FY2023 · CA · contact PI
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors$417,500
R01 · FY2023 · CA · contact PI
Non-genomic resistance mechanisms in EGFR-mutant lung cancer$392,337
R01 · FY2023 · CA · contact PI
High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers$554,744
U01 · FY2022 · CA
Mechanisms driving lung cancer evolution during targeted kinase inhibitor treatment$528,039
R01 · FY2022 · CA · contact PI
Non-genomic resistance mechanisms in EGFR-mutant lung cancer$408,487
R01 · FY2022 · CA · contact PI
High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers$753,506
U01 · FY2021 · CA
Mechanisms driving lung cancer evolution during targeted kinase inhibitor treatment$533,224
R01 · FY2021 · CA · contact PI
High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizers$616,064
U01 · FY2020 · CA
Mechanisms driving lung cancer evolution during targeted kinase inhibitor treatment$537,609
R01 · FY2020 · CA · contact PI
Evolution of resistance of EGFR mutant non-small cell lung cancer$179,280
K08 · FY2020 · CA · contact PI
Evolution of resistance of EGFR mutant non-small cell lung cancer$179,280
K08 · FY2019 · CA · contact PI
Evolution of resistance of EGFR mutant non-small cell lung cancer$179,280
K08 · FY2018 · CA · contact PI
Evolution of resistance of EGFR mutant non-small cell lung cancer$179,280
K08 · FY2017 · CA · contact PI
Evolution of resistance of EGFR mutant non-small cell lung cancer$179,280
K08 · FY2016 · CA · contact PI